P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032
Swaminathan Iyer,
Deepa Jagadeesh,
Eva Domingo Domènech,
Fabio Benedetti,
Antonia Rodriguez Izquierdo,
Kamal Bouabdallah,
Umberto Vitolo,
Tim Illidge,
Jingmin Liu,
Scott Knowles,
Steven Horwitz
Affiliations
Swaminathan Iyer
1 The University of Texas MD Anderson Cancer Center, Houston,TX, United States
Deepa Jagadeesh
2 Cleveland Clinic Taussig Cancer Center, Cleveland, OH, United States
Eva Domingo Domènech
3 Institut Català d’Oncologia - Hospital Duran i Reynals, Barcelona, Spain
Fabio Benedetti
4 University of Verona, Verona, Italy
Antonia Rodriguez Izquierdo
5 Hospital 12 de Octubre, Madrid, Spain
Kamal Bouabdallah
6 CHU Haut-Leveque, Service d’hematologie clinique et therapie cellulaire, Pessac, France
Umberto Vitolo
7 Oncological Institute Candiolo, Candiolo, Italy
Tim Illidge
8 The Christie NHS Foundation Trust, Manchester, United Kingdom
Jingmin Liu
9 Seagen Inc., Bothell, WA, United States
Scott Knowles
9 Seagen Inc., Bothell, WA, United States
Steven Horwitz
10 Memorial Sloan Kettering Cancer Center New York, New York, NY, United States
